Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
Nicholls, Stephen J; Nelson, Adam J.
Am J Cardiovasc Drugs
; 19(4): 343-348, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-30680652
Biomedical research in france and brazil: an analysis of significant differences and ethical issues
Antiplatelet and anticoagulation for patients with prosthetic heart valves.
Antiplatelet agents and anticoagulants for hypertension.
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.
Antithrombin III for critically ill patients.
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.